C4 Therapeutics annual depreciation and amortization
2019
2020
2021
2022
2023
2024
2025
C4 Therapeutics Depreciation & Amortization Growth & History (CCCC)
C4 Therapeutics's depreciation and amortization was $2.0M for fiscal 2025.
View full C4 Therapeutics company overviewC4 Therapeutics annual depreciation and amortization history
| Fiscal year | Period ended | Depreciation and amortization | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $2.0M | $141,000 | +7.76% |
| 2024 | 2024-12-31 | $1.8M | −$62,000 | −3.30% |
| 2023 | 2023-12-31 | $1.9M | $204,000 | +12.17% |
| 2022 | 2022-12-31 | $1.7M | $184,000 | +12.33% |
| 2021 | 2021-12-31 | $1.5M | −$125,000 | −7.73% |
| 2020 | 2020-12-31 | $1.6M | $22,000 | +1.38% |
| 2019 | 2019-12-31 | $1.6M | — | — |
C4 Therapeutics quarterly depreciation and amortization
Q1.20
Q2.20
Q3.20
Q1.21
Q2.21
Q3.21
Q1.22
Q2.22
Q3.22
Q1.23
Q2.23
Q3.23
Q1.24
Q2.24
Q3.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Depreciation and amortization | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $292,000 | −$323,000 | −52.52% |
| Q1 2026 | 2026-03-31 | $404,000 | −$52,000 | −11.40% |
| Q4 2025 | 2025-12-31 | $428,000 | — | — |
| Q3 2025 | 2025-09-30 | $460,000 | $18,000 | +4.07% |
| Q2 2025 | 2025-06-30 | $615,000 | $167,000 | +37.28% |
| Q1 2025 | 2025-03-31 | $456,000 | $8,000 | +1.79% |
| Q3 2024 | 2024-09-30 | $442,000 | −$5,000 | −1.12% |
| Q2 2024 | 2024-06-30 | $448,000 | −$10,000 | −2.18% |
| Q1 2024 | 2024-03-31 | $448,000 | −$97,000 | −17.80% |
| Q3 2023 | 2023-09-30 | $447,000 | $32,000 | +7.71% |
| Q2 2023 | 2023-06-30 | $458,000 | $23,000 | +5.29% |
| Q1 2023 | 2023-03-31 | $545,000 | $240,000 | +78.69% |
| Q3 2022 | 2022-09-30 | $415,000 | $85,000 | +25.76% |
| Q2 2022 | 2022-06-30 | $435,000 | $47,000 | +12.11% |
| Q1 2022 | 2022-03-31 | $305,000 | −$146,000 | −32.37% |
| Q3 2021 | 2021-09-30 | $330,000 | −$90,000 | −21.43% |
| Q2 2021 | 2021-06-30 | $388,000 | −$28,000 | −6.73% |
| Q1 2021 | 2021-03-31 | $451,000 | $35,000 | +8.41% |
| Q3 2020 | 2020-09-30 | $420,000 | — | — |
| Q2 2020 | 2020-06-30 | $416,000 | — | — |
| Q1 2020 · Mar 31 | 2020-03-31 | $416,000 | — | — |
C4 Therapeutics depreciation and amortization trends
Over the last five fiscal years, C4 Therapeutics's depreciation and amortization increased from $1.6M to $2.0M, a change of $342,000. The latest reported quarter, Q2 2026, shows $292,000.
About the metric
What depreciation and amortization mean
Depreciation and amortization allocate the cost of tangible and intangible assets over their useful lives. These non-cash expenses reduce reported earnings and are commonly added back when calculating EBITDA and operating cash flow.
Calculation and source
Reported depreciation and amortization
TickerStat uses a combined depreciation and amortization value when reported. If a company reports the two components separately for an aligned period, they are added together without duplicating overlapping facts. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review C4 Therapeutics source filings ↗